Antisense approaches in prostate cancer

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 927-936

  Chi, Kim N ^a   Gleave, Martin E ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen receptor; Antisense oligonucleotides; Apoptosis; Cell signalling; Prostate cancer

Indexed keywords

AEG 35156; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; AS 750 15; CGP 69846A; CLUSTERIN; DACARBAZINE; DOCETAXEL; GEM 240; GROWTH FACTOR; GTI 2040; GTI 2501; INHIBITOR OF APOPTOSIS PROTEIN; ISIS 3521; LY 2181308; MESSENGER RNA; MITOXANTRONE; OBLIMERSEN; OGX 011; OGX 225; PROTEIN BCL 2; PROTEIN BCL XL; RAF PROTEIN; RECOMBINANT DNA; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ANOREXIA; APOPTOSIS; CANCER GROWTH; CLINICAL TRIAL; FATIGUE; GENE EXPRESSION REGULATION; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOPHOSPHATEMIA; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

APOPTOSIS; CLUSTERIN; DISEASE PROGRESSION; GLYCOPROTEINS; GROWTH SUBSTANCES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MALE; MODELS, GENETIC; MOLECULAR CHAPERONES; NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 3042645268     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.927     Document Type: Review

References (97)

1. JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA Cancer J. Clin. (2003) 53(1):5-26.
2. D'AMICO AV, WHITTINGTON R, MALKOWICZ SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 280(11):969-974.
3. TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. (1996) 14(6):1756-1764.
4. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J. Clin. Oncol. (1999) 17(8):2506-2513.
5. BEER TM, PIERCE WC, LOWE BA et al.: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. (2001) 12(9):1273-1279.
6. PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. (Huntingt.) (1999) 26(5 Suppl. 17):14-18.
7. LUO J, DUGGAN DJ, CHEN Y et al.: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. (2001) 61(12):4683-4688.
8. PATERSON BM, ROBERTS BE, KUFF EL: Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad Sci. USA (1977) 74:4370-4374.
9. ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280-294.
10. CROOKE ST: Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. (1998) 8(2):133-134.
11. CARPENTIER AF, CHEN L, MALTONTI F, DELATTRE JY: Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. (1999) 59(21):5429-5432.
12. JANSEN B, SCHLAGBAUER-WADL H, BROWN BD et al.: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. (1998) 4(2):232-234.
13. LEONETTI C, BIROCCIO A, BENASSI B et al.: Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. (2001) 8(6):459-468.
14. MORRIS MJ, TONG WP, CORDON-CARDO C et al.: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. (2002) 8(3):679-683.
15. ZELLWEGER T, MIYAKE H, COOPER S et al.: Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy) ethyl chemistry. J. Pharmacol. Exp. Ther. (2001) 298(3):934-940.
16. CHI KN, GLEAVE ME, KLASA R et al.: A Phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. (2001) 7(12):3920-3927.
17. TOLCHER AW, REYNO L, VENNER PM et al.: A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. (2002) 8(8):2530-2535.
18. WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. (2000) 18(9):1812-1823.
19. HENRY S, STECKER K, BROOKS D, MONTEITH D, CONKLIN B, BENNETT CF: Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. (2000) 292(2):468-479.
20. BUBENDORF L, KOLMER M, KONONEN J et al.: Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl. Cancer Inst. (1999) 91(20):1758-1764.
21. MIYAKE H, TOLCHER A, GLEAVE ME: Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. (1999) 59(16):4030-4034.
22. MIYAKE H, NELSON C, RENNIE PS, GLEAVE ME: Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. (2000) 60(1):170-176.
23. NICKERSON T, MIYAKE H, GLEAVE ME, POLLAK M: Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res. (1999) 59(14):3392-3395.
24. CRAFT N, SHOSTAK Y, CAREY M, SAWYERS CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. (1999) 5(3):280-285.
25. GLEAVE M, TOLCHER A, MIYAKE H et al.: Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. (1999) 5(10):2891-2898.
26. GROSSFELD GD, OLUMI AF, CONNOLLY JA et al.: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J. Urol. (1998) 159(5):1437-1443.
27. CULIG Z, HOBISCH A, CRONAUER MV et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 28(6):392-405.
28. FELDMAN BJ, FELDMAN D: The development of androgen-independent prostate cancer. Nat. Rev. Cancer (2001) 1(1):34-45.
29. TSUJIMOTO Y, CROCE CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad Sci. USA (1986) 83(14):5214-5218.
30. REED JC: Bcl-2 and the regulation of programmed cell death. J. Cell Biol. (1994) 124(1-2):1-6.
31. MIYASHITA T, REED JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood (1993) 81(1):151-157.
32. KYPRIANOU N, KING ED, BRADBURY D, RHEE JG: bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer (1997) 70(3):341-348.
33. MCDONNELL TJ, NAVONE NM, TRONCOSO P et al.: Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol. (1997) 157(2):569-574.
34. COLOMBEL M, SYMMANS F, GIL S et al.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. (1993) 143(2):390-400.
35. MCDONNELL TJ, TRONCOSO P, BRISBAY SM et al.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. (1992) 52(24):6940-6944.
36. RAFFO AJ, PERLMAN H, CHEN MW, DAY ML, STREITMAN JS, BUTTYAN R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. (1995) 55(19):4438-4445.
37. BUBENDORF L, SAUTER G, MOCH H et al.: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol. (1996) 148(5):1557-1565.
38. SCHERR DS, VAUGHAN ED JR, WEI J et al.: BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol. (1999) 162(1):12-16.
39. LEUNG S, MIYAKE H, ZELLWEGER T, TOLCHER A, GLEAVE ME: Synergistic chemosensitization and inhibition of progression to androgen independence by intisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer (2001) 91(6):846-850.
40. DE BONO JS, ROWINSKY EK, KUHN J et al.: Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of bcl-2 antisense (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proceedings of the American Society of Clinical Oncology Thirty-seventh Annual Meeting. San Francisco, USA (2001) 20:119a (Abstract 474).
41. CHI KN, MURRAY RN, GLEAVE ME et al.: A Phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC). Proceedings of the American Society of Clinical Oncology Thirty-seventh Annual Meeting. San Francisco, USA (2003) 22:393 (Abstract 1580).
42. MIYAKE H, MONIA BP, GLEAVE ME: Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int. J. Cancer (2000) 86(6):855-862.
43. STEINBERG J, OYASU R, LANG S et al.: Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. (1997) 3(10):1707-1711.
44. CERVELLERA M, RASCHELLA G, SANTILLI G et al.: Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J. Biol. Chem. (2000) 275(28):21055-21060.
45. REDONDO M, VILLAR E, TORRES-MUNOZ J, TELLEZ T, MORELL M, PETITO CK: Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. (2000) 157(2):393-399.
46. WELLMANN A, THIEBLEMONT C, PITTALUGA S et al.: Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood (2000) 96(2):398-404.
47. MIYAKE H, GLEAVE M, KAMIDONO S, HARA I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology (2002) 59(1):150-154.
48. PARCZYK K, PILARSKY C, RACHEL U, KOCH-BRANDT C: Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J. Cancer Res. Clin. Oncol. (1994) 120(3):186-188.
49. CALERO M, ROSTAGNO A, MATSUBARA E, ZLOKOVIC B, FRANGIONE B, GHISO J: Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. (2000) 50(4):305-315.
50. ROSENBERG ME, SILKENSEN J: Clusterin and the kidney. Exp. Nephrol. (1995) 3(1):9-14.
51. MONTPETIT ML, LAWLESS KR, TENNISWOOD M: Androgen-repressed messages in the rat ventral prostate. Prostate (1986) 8(1):25-36.
52. KYPRIANOU N, ENGLISH HF, ISAACS JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. (1990) 50(12):3748-3753.
53. JULY LV, AKBARI M, ZELLWEGER T, JONES EC, GOLDENBERG SL, GLEAVE ME: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate (2002) 50(3):179-188.
54. KOCH-BRANDT C, MORGANS C: Clusterin: a role in cell survival in the face of apoptosis? Prog. Mol. Subcell. Biol. (1996) 16:130-149.
55. WILSON MR, EASTERBROOK-SMITH SB: Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. (2000) 25(3):95-98.
56. MICHEL D, CHATELAIN G, NORTH S, BRUN G: Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. (1997) 328(1):45-50.
57. HUMPHREYS DT, CARVER JA, EASTERBROOK-SMITH SB, WILSON MR: Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. (1999) 274(11):6875-6881.
58. SENSIBAR JA, SUTKOWSKI DM, RAFFO A et al.: Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. (1995) 55(11):2431-2437.
59. ZELLWEGER T, CHI K, MIYAKE H et al.: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. (2002) 8(10):3276-3284.
60. MIYAKE H, CHI KN, GLEAVE ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. (2000) 6(5):1655-1663.
61. DEVERAUX QL, ROY N, STENNICKE HR et al.: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. (1998) 17(8):2215-2223.
62. ROY N, DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. (1997) 16(23):6914-6925.
63. DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 388(6639):300-304.
64. TAMM I, WANG Y, SAUSVILLE E et al.: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. (1998) 58(23):5315-5320.
65. LEVKAU B, GARTON KJ, FERRI N et al.: xIAP induces cell-cycle arrest and activates nuclear factor-kappaB: new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ. Res. (2001) 88(3):282-290.
66. SILKE J, HAWKINS CJ, EKERT PG et al.: The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J. Cell Biol. (2002) 157(1):115-124.
67. SALVESEN GS, DUCKETT CS: IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. (2002) 3(6):401-410.
68. KRAJEWSKA M, KRAJEWSKI S, BANARES S et al.: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. (2003) 9(13):4914-4925.
69. PATEL BK, CARRASCO RA, STAMM NB et al.: Antisense inhibition of survivin expression as a cancer therapeutic. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, USA (2003) Abstract B62.
70. HU Y, CHERTON-HORVAT G, DRAGOWSKA V et al.: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. (2003) 9(7):2826-2836.
71. LEITE KR, FRANCO MF, SROUGI M et al.: Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol. (2001) 14(5):428-436.
72. STAPLETON AM, TIMME TL, GOUSSE AE et al.: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin. Cancer Res. (1997) 3(8):1389-1397.
73. AGUS DB, CORDON-CARDO C, FOX W et al.: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. (1999) 91(21):1869-1876.
74. WANG H, YU D, AGRAWAL S, ZHANG R: Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate (2003) 54(3):194-205.
75. ZHANG Z, LI M, WANG H, AGRAWAL S, ZHANG R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA (2003) 100(20):11636-11641.
76. SIGALAS I, CALVERT AH, ANDERSON JJ, NEAL DE, LUNEC J: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. (1996) 2(8):912-917.
77. JONES SN, HANCOCK AR, VOGEL H, DONEHOWER LA, BRADLEY A: Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA (1998) 95(26):15608-15612.
78. GU L, FINDLEY HW, ZHOU M: MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood (2002) 99(9):3367-3375.
79. FU H, XIA K, PALLAS DC et al.: Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science (1994) 266(5182):126-129.
80. KOLCH W, HEIDECKER G, KOCHS G et al.: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature (1993) 364(6434):249-252.
81. NEWTON AC: Regulation of protein kinase C. Curr. Opin. Cell Biol. (1997) 9(2):161-167.
82. LIU B, MAHER RJ, HANNUN YA, PORTER AT, HONN KV: 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J. Natl. Cancer Inst. (1994) 86(15):1145-1151.
83. O'BRIAN CA: Protein kinase C-alpha: a novel target for the therapy of androgen-independent prostate cancer? Oncol. Rep. (1998) 5(2):305-309.
84. NEMUNAITIS J, HOLMLUND JT, KRAYNAK M et al.: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. (1999) 17(11):3586-3595.
85. YUEN AR, HALSEY J, FISHER GA et al.: Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. (1999) 5(11):3357-3363.
86. CUNNINGHAM CC, HOLMLUND JT, SCHILLER JH et al.: A Phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. (2000) 6(5):1626-1631.
87. JONES JI, CLEMMONS DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. (1995) 16(1):3-34.
88. NICKERSON T, POLLAK M, HUYNH H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology (1998) 139(2):807-810.
89. FIGUEROA JA, DE RAAD S, TADLOCK L, SPEIGHTS VO, RINEHART JJ: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol. (1998) 159(4):1379-1383.
90. MIYAKE H, NELSON C, RENNIE PS, GLEAVE ME: Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology (2000) 141(6):2257-2265.
91. MIYAKE H, POLLAK M, GLEAVE ME: Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. (2000) 60(11):3058-3064.
92. KIYAMA S, MORRISON K, ZELLWEGER T et al.: Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. (2003) 63(13):3575-3584.
93. SCHER HI, KELLY WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. (1993) 11(8):1566-1572.
94. EDER IE, CULIG Z, RAMONER R et al.: Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. (2000) 7(7):997-1007.
95. EDER IE, HOFFMANN J, ROGATSCH H et al.: Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. (2002) 9(2):117-125.
96. HAMY F, BRONDANI V, SPOERRI R, RIGO S, STAMM C, KLIMKAIT T: Specific block of androgen receptor activity by antisense oligonucleotides. Prostate Cancer Prostatic Dis. (2003) 6(1):27-33.
97. LYNCH TJ, RAJU R, LIND M et al.: Randomized Phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proceedings of the American Society of Clinical Oncology Thirty-seventh Annual Meeting. San Francisco, USA (2003) 22:623 (Abstract 2504).